Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

12.15 -0.20 (-1.62%)
Streaming Delayed Price Updated: 11:55 AM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
News headline image
3 Small-Cap Stocks Walking a Fine Line
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav... 
Via StockStory
Topics Stocks
News headline image
3 Value Stocks We’re Skeptical Of
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Why Amneal (AMRX) Stock Is Trading Lower Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a... 
Via StockStory
News headline image
Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗
Amneal (AMRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand,... 
Via StockStory
News headline image
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates
In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
3 Russell 2000 Stocks We Find Risky
Via StockStory
News headline image
3 Small-Cap Stocks That Fall Short
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
3 Cash-Producing Stocks That Concern Us
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also... 
Via StockStory
Topics Stocks
News headline image
2 Reasons to Sell AMRX and 1 Stock to Buy Instead
Amneal has been on fire lately. In the past six months alone, the company’s stock price has rocketed 63.3%, reaching $13.34 per share. This was partly thanks to its solid quarterly results, and the... 
Via StockStory
News headline image
1 Small-Cap Stock to Target This Week and 2 That Underwhelm
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
3 Healthcare Stocks We’re Skeptical Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,... 
Via StockStory
Topics Stocks
News headline image
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗
The pharmaceutical company has experienced sales growth over the past five years. 
Via The Motley Fool
News headline image
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs ↗
One executive’s option-linked sale may look large on paper, but the broader context tells a more nuanced story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks
Looking back on generic pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Amneal (NASDAQ:AMRX) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Russell 2000 Stocks with Warning Signs
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
News headline image
3 Stocks Under $50 We Steer Clear Of
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Value Stocks We Find Risky
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Why Amneal (AMRX) Stock Is Up Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 8.9% in the afternoon session after the company reported strong third-quarter financial results that surpassed expectations... 
Via StockStory
News headline image
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Q3 2025 Earnings: EPS Beats Estimates, Stock Surges on Raised Guidance ↗
Amneal Pharmaceuticals Q3 2025 earnings beat profit estimates, driving a stock surge. The company also raised its full-year guidance for EBITDA and EPS. 
Via Chartmill
Topics Earnings
News headline image
Amneal (NASDAQ:AMRX) Beats Q3 Sales Expectations, Stock Soars
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.7% year on year to $784.5 million. The company’s... 
Via StockStory
News headline image
Amneal Earnings: What To Look For From AMRX
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Thursday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.